Glycomine

Glycomine aims to develop a new generation of rare disease replacement therapies. The company's drugs include orphan drugs that combine replacement therapies (substrates, enzymes, or proteins) with intracellular delivery carriers, which are composed of bionanomaterials or ligands, targeting molecules to the interiors of cells in clinically relevant organs, enabling doctors to seriously treat rare monogenic metabolic disorders and protein misfolding.